JOURNEY MEDICAL CORP (DERM)
US48115J1097 - Common Stock
DERM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. DERM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year DERM has reported negative net income.
In the past year DERM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: DERM reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -5.01%, DERM is in the better half of the industry, outperforming 77.44% of the companies in the same industry.
DERM has a better Return On Equity (-18.93%) than 75.38% of its industry peers.
DERM has a better Return On Invested Capital (2.43%) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.01% | ||
| ROE | -18.93% | ||
| ROIC | 2.43% |
ROA(3y)-26.13%
ROA(5y)-11.5%
ROE(3y)-99.32%
ROE(5y)-23.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of DERM (1.36%) is better than 77.44% of its industry peers.
In the last couple of years the Operating Margin of DERM has declined.
DERM has a Gross Margin of 66.33%. This is in the better half of the industry: DERM outperforms 69.23% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.36% | ||
| PM (TTM) | N/A | ||
| GM | 66.33% |
OM growth 3Y-57.52%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-7.36%
2. Health
2.1 Basic Checks
DERM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for DERM has been increased compared to 1 year ago.
The number of shares outstanding for DERM has been reduced compared to 5 years ago.
DERM has a better debt/assets ratio than last year.
2.2 Solvency
DERM has an Altman-Z score of 0.50. This is a bad value and indicates that DERM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.50, DERM perfoms like the industry average, outperforming 56.41% of the companies in the same industry.
DERM has a debt to FCF ratio of 73.42. This is a negative value and a sign of low solvency as DERM would need 73.42 years to pay back of all of its debts.
DERM has a better Debt to FCF ratio (73.42) than 77.44% of its industry peers.
DERM has a Debt/Equity ratio of 0.72. This is a neutral value indicating DERM is somewhat dependend on debt financing.
DERM has a Debt to Equity ratio of 0.72. This is in the lower half of the industry: DERM underperforms 67.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 73.43 | ||
| Altman-Z | 0.5 |
ROIC/WACC0.31
WACC7.93%
2.3 Liquidity
A Current Ratio of 1.35 indicates that DERM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.35, DERM is not doing good in the industry: 77.44% of the companies in the same industry are doing better.
DERM has a Quick Ratio of 1.10. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
DERM's Quick ratio of 1.10 is on the low side compared to the rest of the industry. DERM is outperformed by 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 89.29% over the past year.
DERM shows a small growth in Revenue. In the last year, the Revenue has grown by 7.46%.
DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.34% yearly.
EPS 1Y (TTM)89.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q80%
Revenue 1Y (TTM)7.46%
Revenue growth 3Y21.15%
Revenue growth 5Y13.34%
Revenue growth Q2Q-4.46%
3.2 Future
The Earnings Per Share is expected to decrease by -32.45% on average over the next years. This is quite bad
Based on estimates for the next years, DERM will show a small growth in Revenue. The Revenue will grow by 0.30% on average per year.
EPS Next Y-319.33%
EPS Next 2Y-6.46%
EPS Next 3Y-32.45%
EPS Next 5YN/A
Revenue Next Year-26.61%
Revenue Next 2Y1.88%
Revenue Next 3Y0.3%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DERM. In the last year negative earnings were reported.
Also next year DERM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DERM indicates a rather cheap valuation: DERM is cheaper than 90.26% of the companies listed in the same industry.
DERM's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DERM is cheaper than 77.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 197.34 | ||
| EV/EBITDA | 8.04 |
4.3 Compensation for Growth
A cheap valuation may be justified as DERM's earnings are expected to decrease with -32.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.46%
EPS Next 3Y-32.45%
5. Dividend
5.1 Amount
No dividends for DERM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JOURNEY MEDICAL CORP
NASDAQ:DERM (4/26/2024, 7:00:00 PM)
3.4
-0.1 (-2.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap47.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.01% | ||
| ROE | -18.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 1.36% | ||
| PM (TTM) | N/A | ||
| GM | 66.33% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)89.29%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-319.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.46%
Revenue growth 3Y21.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y